Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Exelixis Inc before investing.

In this article, we go over a few key elements for understanding Exelixis Inc’s stock price such as:

• Exelixis Inc’s current stock price and volume
• Why Exelixis Inc’s stock price changed recently
• Upgrades and downgrades for EXEL from analysts
• EXEL’s stock price momentum as measured by its relative strength

About Exelixis Inc (EXEL)

Before we jump into Exelixis Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Want to learn more about Exelixis Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Exelixis Inc.

Exelixis Inc’s Stock Price as of Market Close

As of May 31, 2024, 3:59 PM, CST, Exelixis Inc’s stock price was $21.69.

Exelixis Inc is up 4.38% from its previous closing price of $20.78.

During the last market session, Exelixis Inc’s stock traded between $20.40 and $20.89. Currently, there are 300.76 million shares of Exelixis Inc stock available for purchase.

Exelixis Inc’s price-earnings (P/E) ratio is currently at 32.1, which is high compared to the Biotechnology & Medical Research industry median of 28.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Exelixis Inc Stock Price History

Exelixis Inc’s (EXEL) price is currently down 7.54% so far this month.

During the month of May, Exelixis Inc’s stock price has reached a high of $22.47 and a low of $20.14.

Over the last year, Exelixis Inc has hit prices as high as $24.34 and as low as $18.64. Year to date, Exelixis Inc’s stock is up 35.22%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Exelixis Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 30, 2024, there were 5 analysts who downgraded Exelixis Inc’s stock and 5 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Exelixis Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Exelixis Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Exelixis Inc’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Exelixis Inc (EXEL) by visiting AAII Stock Evaluator.

Relative Price Strength of Exelixis Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 30, 2024, Exelixis Inc has a weighted four-quarter relative price strength of -4.44%, which translates to a Momentum Score of 48 and is considered to be Average.

Want to learn more about how Exelixis Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Exelixis Inc Stock Price: Bottom Line

As of May 31, 2024, Exelixis Inc’s stock price is $21.69, which is up 4.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Exelixis Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.